Kornimate/medical-research-clean huggingface dataset:
morbimortality in major urgent general surgery in the geriatric patient.

Conditions: Surgery--Complications; Emergencies

Summary: retrospective observational cohort study of geriatric patients operated of urgent major general surgery in our centre during 2018. our principal goals are: 1. to evaluate the incidence of post operation complications and its severity (defined by the claiven-dindo scale) 2. to evaluate the mortality: global mortality and mortality after: 30 days, 6 months and 1 year.


Eligibility criteria:
inclusion criteria: * surgeries on the small and / or large bowel with or without intestinal resection, total colectomies, exploratory laparotomies exclusion criteria: * polytraumatic patient, reoperations (for any cause) of scheduled and urgent surgeries
procalcitonin reveals early dehiscence in pancreatic surgery: the predips study

Conditions: Pancreatic Cancer

Summary: background. pancreatic cancer surgery is associated with very high risk of postoperative morbidity and mortality. anastomotic leak (al) is one of the worst complications associated with relevant short and long-term sequelae. procalcitonin (pct) is a biomarker used to monitor bacterial infections and guide antibiotic therapy and has been shown to have better predictive value of al after colorectal surgery than c-reactive protein (crp) and white blood cell count (wbc). purpose. the investigators designed a monocentric pilot study to test if pct might be a sensitive and reliable marker of al after pancreatic surgery


Eligibility criteria:
inclusion criteria: * patients undergoing all different kinds of pancreatic surgery * in elective setting * for cancer * with a pancreatic anastomosis performed. exclusion criteria: * age \< 18 years * pregnant women * patients undergoing pancreatic surgery for benign disease, other kinds of pancreatic surgery without an anastomosis being performed

Keywords: pancreatic cancer procalcitonin
ed ultrasonographic regional anesthesia to prevent incident delirium in hip fracture patients

Conditions: Hip Fractures; Delirium

Summary: hip fractures are common, costly and affect older people - canadians spend 1 billion dollars to treat hip fractures each year. unfortunately, as many as two-thirds of hip fracture cases suffer a complication known as delirium, or acute confusion. patients with delirium may become frightened and agitated. this in turn leads to other serious problems. having delirium doubles the chances of dying or can increase the need for admission into a nursing home. people with delirium spend an extra week in hospital on average. using ultrasound to locate and 'freeze' or block specific nerves can stop hip fracture pain almost immediately, and use of this technique is known to reduce delirium when administered by anaesthetists to patients at the time of their hip operation. unfortunately, patients with hip fractures commonly wait hours or even days in the emergency department (ed) prior to their operation. currently, these patients are given narcotic pain killers like morphine to dull their pain, as most ed physicians have not been trained in using this 'freezing' technique and anaesthetists are rarely able to leave the operating room to administer freezing to patient in the ed. the edu-rapid study will test whether training ed physicians on how to use the nerve freezing technique will reduce the number of patients who develop delirium after a hip fracture. to study this, ed physicians will be trained at 6 hospitals in small groups every 6 weeks over 18 months. the study will look at how patients who are treated by ed physician who has been trained compare to patients treated by a ed physician who has not yet been trained. also, the study will see if the training motivates ed physicians to use the block regularly. if correct, this study could significantly improve the comfort, quality of life, and independence of patients who suffer a hip fracture. in addition, if the study shows a reduction in delirium rates, this could represent a significant cost reduction to the health care system.


Eligibility criteria:
inclusion criteria: * at the cluster level, ed physicians practicing at a participating site will be eligible. * at the patient level, all hip fractures seen by a participating ed physician will be eligible exclusion criteria: * ed physicians who work casually (less than 0.25 full time equivalent) * ed physicians who are routinely using u/s guided ra for hip fracture patients, or decline participation in the trial. * patients' age less than 65 years; * patients who are delirious on initial assessment by ed physician or severe dementia * patients with communication problems (critically ill, unconscious, language barrier despite use of secure telephone-based translation service) * patients with allergies to narcotics or local anesthetic; or anticoagulant use (e.g. warfarin, dabigatran, rivaroxaban). * patients with hip fractures not requiring surgery (e.g. greater trochanter avulsion) will also be excluded.

Keywords: regional anesthesia ultrasound guided emergency department knowledge to practice intervention
randomized trial of exercise promotion in primary care

Conditions: PreDiabetes; Diabetes; Sedentary Behavior

Summary: millions of americans have diabetes or prediabetes, for which regular physical activity can reduce risks of unfavorable outcomes of these conditions. this study will test the effects of an evidence-based intervention in the primary care setting on increasing physical activity among these individuals. if effective, it can be broadly implemented in primary care.


Eligibility criteria:
inclusion criteria: able to speak english or spanish, inactive defined as less than 30 minutes of mvpa per week, prediabetes or diabetes not prescribed insulin, kaiser permanente member for at least 12 months, receives primary care at the fontana medical center, body mass index between 18.5 and 40 kg/m2, exclusion criteria: current use of insulin, cardiovascular event in the past 6 months or other condition that limits physical activity, pregnancy, breastfeeding or planning pregnancy in next 2 years, current participation in another clinical trial or research study, plans to move out of the area in next 2 years,

Keywords: physical activity randomized trial primary care
grafting of the peri-implant bony defects around immediate implants using xenogenic versus alloplastic sticky grafts: randomized controlled clinical trial

Conditions: Bone Loss, Alveolar

Summary: in patients with a single non restorable tooth, does filling the peri-implant buccal gap with alloplastic sticky grafts result comparable results compared to xenogenic sticky grafts?

the buccal aspect of the dental implant has great importance, especially in the aesthetic zone, because the buccal bone is very thin especially in the anterior maxilla and its resorption can result in recession of the soft tissue. a gap occurs in immediately placed implant due to discrepancy between the dimensions of the extraction socket and the implant. augmentation of the buccal gap decreases the amount of buccal bone resorption and soft tissue recession . filling the peri-implant defects has been widely discussed to prevent further bone loss. the use of biologic materials such as platelet rich fibrin can enhance the quality of alloplastic bone grafts to give comparable effect when compared to xenogenic grafts.

Eligibility criteria:
inclusion criteria: 1. patients with healthy systemic condition (mazzotti et al., 2023). 2. age from 20-50 years old 3. patients must be free of any systemic disease which could influence the surgical procedure. 4. tooth involved in the esthetic zone. 5. sufficient hard and soft tissue volume in vertical and buccolingual direction 6. natural teeth adjacent to the involved tooth will be required to be free from infection. 7. controlled oral hygiene. 8. indication for tooth extraction included (degidi et al., 2012); * endodontic failures * untreatable caries * non- restorable teeth * vertical root fracture * remaining roots exclusion criteria: - 1.pregnant females 2.smokers (khuller, 2009) 3.unmotivated and uncooperative patients with poor oral hygiene 4.patients with habits that may compromise the longevity and affect the result of the study as alcoholism or parafunctional habits. 5.presence of acute dento-alveolar infection.
study of endoscopic sphincterotomy with needle knife papillotome in patients of ampullary impacted stone

Conditions: Choledocholithiasis; Endoscopy

Summary: using a needle knife papillotome by an experienced endoscopist, endoscopic sphincterotomies were performed in difficult cannulation cases. in a prospectively collected database, we investigate the complications of those with ampullary impacted stone.

the endoscopic sphincterotomy with needle knife papillotome is a well-established advanced endoscopic technique in difficult cannulation cases. choledocholithiasis impacted at the ampulla of vater is occasionally seen. inflammed surrounding mucosa frequently accompanies. whether sphincterotomy with a needle knife increases the bleeding complications is to be elucidated in this study.

Eligibility criteria:
inclusion criteria: * choledocholithiasis patients and an ampullary impacted stone exclusion criteria: * patients with liver cirrhosis , pregnancy, history of abdominal malignancy, bleeding diathesis, ileus, renal failure

Keywords: sphincterotomy needle knife hemorrhage complication
non-invasive brain stimulation (nibs) and dual-task walking after stroke

Conditions: Stroke

Summary: the study aims to identify neural locus critical for dual-task walking (walking and talking) in individuals with stroke. to achieve this aim, the investigators apply repetitive transcranial magnetic stimulation (rtms) to different parts of the brain and evaluate the effects of brain stimulation on dual-task walking speed.

this study will enroll 12 individuals with a stroke at least 6 months ago. participants will be tested across 3 sessions and each session will be approximately 1 week apart from each other. during testing, participants will be asked to walk under two conditions: single- and dual-task conditions. under the single-task condition, participants walk on a instrumented mat such that their gait performance will be captured. under the dual-task condition, participants walk on the mat while performing a counting backward task. the walking assessment is followed by a 12 minute non-invasive brain stimulation using high frequency rtms. another walking assessment will be conducted right after the brain stimulation session. high frequency rtms will be applied to different neural loci, namely primary motor cortex (m1), supplementary motor area (sma), and dorsolateral prefrontal cortex (dlpfc). the walking speed under two different conditions will be compared before and after brain stimulation to different neural loci.

Eligibility criteria:
inclusion criteria: 1. age above 18 years 2. diagnosis of left hemispheric stroke at least 6 months ago 3. first time stroke or complete gait recovery from prior stroke 4. able to walk independently for at least 10 meters with or without walking aids 5. have at least minimal movements (\> 5 degree of motion) at the affected ankle 6. score \> 26 on mini mental state exam (mmse) 7. ability to participate in the informed consent process exclusion criteria: 1. diagnosis of other neurological conditions, such as parkinson disease, alzheimer, spinal cord injury, multiple sclerosis 2. other comorbidities which could interfere with gait (i.e. amputation, severe osteoarthritis) 3. unstable clinical conditions 4. non-ambulatory prior to onset of stroke 5. history of significant head trauma 6. electrical, magnetic, or mechanical implantation: cardiac pacemakers or intracerebral vascular clip 7. metal implantation in the oral cavity, head/neck area and lower extremity 8. pregnancy 9. history of seizures or unexplained loss of consciousness 10. immediate family member with epilepsy 11. use of seizure threshold lowering medicine 12. current abuse of alcohol or drugs 13. anticipated inability to complete the study 14. history of psychiatric illness requiring medication control
atrial appendage closure prospective observational study

Conditions: Atrial Fibrillation; Left Atrial Appendage Closure

Summary: the purpose of this research is to monitor how well patients do after surgery for treatment of left atrial appendage (laa).

patients will be followed in an observational study. we propose to do a single follow-up tee at 3 to 6 months (this is standard of care) to confirm laa (left atrial appendage) occlusion. the tee is not mandatory (this is not a clinical trial), but will be strongly recommended to patients to confirm the efficacy of treatment. this will help confirm whether patients may safely remain off anticoagulation. the risks of tee are a less than 1 in 1000 risk of death, and a 1% or less risk of a major complication, such as esophageal perforation.

Eligibility criteria:
inclusion criteria: * patients with atrial fibrillation * are poor candidates to take warfarin * have elected to undergo a lariat procedure exclusion criteria: * none

Keywords: left atrial appendage closure
molecular profiling of colorectal cancer

Conditions: Colorectal Cancer; Colon Cancer; Colon Adenocarcinoma

Summary: in this translational research study, formalin-fixed-paraffin-embedded (ffpe) tumor tissue blocks from patients with early-stage (ii-iii) colorectal cancer will be assessed for a comprehensive cancer gene panel from nipd genetics (https://www.nipd.com/) targeting regions in 37 clinically relevant cancer genes. the colorectal cancer panel includes an extended list of clinically relevant genes, designed to target clinically actionable and clinically significant mutations that will provide physicians with genetic information regarding a) prediction of the patient's response to targeted therapy, b) prognosis, that is, prediction of clinical outcome, c) diagnosis and molecular classification of colorectal cancer.


Eligibility criteria:
inclusion criteria: * surgically resected early-stage (ii-iii) colorectal cancer * availability of biological material exclusion criteria: * metastatic disease (stage iv) at initial diagnosis

Keywords: colon translational research gene panel
gender disparity in burn injury survival

Conditions: Obesity; Burn Injury

Summary: hypothesis 1: a quantifiable difference in inflammatory cytokines exist in women with burn injury and this correlates with clinical markers of outcome hypothesis 2: the amount of adipose tissue contributes to the severity of cellular immune response (cmi) dysregulation in response to burn injury skin-fold caliper measurements will be taken on consented patients (both male and female) to determine body fat percentage. serum samples will be obtained from these patients. the level of inflammatory cytokines in the serum will be measured to determine if there is a link between body fat percentage, pro-inflammatory cytokines and the ability of women to survive burn injury.

consented patients admitted to university medical center with greater than 15% total body surface area burns will participate in this study. a skin-fold caliper measurement will be performed to determine body fat percentage. serum samples will be obtained and assayed for inflammatory cytokines to establish whether or not a link between obesity in women and pro-inflammatory cytokines exists. if so, obesity may be a factor which contributes to the gender disparity in burn wound survival.

Eligibility criteria:
inclusion criteria: * men and women ages 18 to 65 years * admitted to university medical center with greater than 15% total body surface area burns * able to provide informed consent or has authorized representative to give informed consent exclusion criteria: * prisoners or pregnant women * individuals with injuries that preclude taking caliper measurements

Keywords: outcome
clinical and device functional assessment of real world icd patients

Conditions: Arrythmia; Implantable Cardioverter Defibrillator

Summary: the primary requirement of the implantable cardioverter defibrillator (icd) is to preserve life by terminating life-threatening arrhythmias (vt/vf). the treatment options vary in terms of techniques and medical devices, based on the patient's condition. it is extremely important in the clinical practice to identify which patients' subgroup benefits the most from the icd therapy, which comorbidity has a major impact on the patients' prognosis, or which pre-intra-post procedural behaviors provoke less complications, and affect the patient's outcome (including prolonged or unwanted hospitalizations).

for these reasons, it is very important to observe the clinical practice on a large variety of centers and countries, with the objective to collect long term safety and performance data in patients undergoing icd/crt-d device implantation (first implant, replacement or upgrade). the safety and performance of the icds can be evaluated through the collection of multiple parameters such as, but not limited to: * clinical parameters, like patient demographics and history, procedural and hospital discharge data, as well as the short and long term serious adverse events (death and hospitalization) * device parameters, such as delivered shocks, atp, or other device therapies worldwide selected centers will be invited to participate in this prospective study and include their "real-world" patients treated with sorin group commercially available icds and crt-ds devices.

Eligibility criteria:
inclusion criteria: * patient implanted (first implant, replacement, upgrade) with a sorin group icd/crt-d device, according to current available guidelines and ifu * signed and dated informed consent (in accordance to local regulation) exclusion criteria: * already included in another clinical study that could confound the results of this study * not available for routine follow-up visits * minor age * drug addiction or abuse

Keywords: clinical and device functional information "real world" icd patient population
phase 1-2 evaluation of ot-730 eye drops in reducing the intraocular pressure in patients with ocular hypertension or open-angle glaucoma

Conditions: Glaucoma, Open-Angle; Ocular Hypertension

Summary: the purpose of this study is to evaluate the safety and potential efficacy of a new drug, ot-730 ophthalmic solution (eye drops), in reducing intraocular pressure in the eyes of patients with open angle glaucoma or ocular hypertension. it will be compared with commercial timolol and placebo eye drops.

glaucoma is a group of diseases of the eye that can result in irreversible vision loss due to damage to the optic nerve. elevated intraocular pressure (iop) is one factor associated with glaucoma. currently-available medication used to lower iop includes beta-blocking agents, which can have undesirable side effects on the cardiac and respiratory systems. the ot-730 ophthalmic solution contains ot-730, a prodrug that, when applied as an eyedrop, metabolizes to ot-705, an active beta blocker. the ot-730 ophthalmic solution is being studied to see how well it lowers iop in patients with a diagnosis of open angle glaucoma or ocular hypertension. it will be compared with a well known beta blocker, timolol maleate ophthalmic solution, and with a placebo eye drop, in order to assess its ability to lower iop without the typical side effects of other beta blockers.

Eligibility criteria:
inclusion criteria: * healthy subjects, 18 to 80 years of age, any gender * diagnosis of primary open angle, pseudoexfoliative or pigmentary glaucoma or ocular hypertension exclusion criteria: * have va worse than 20/200, * cataract that compromises visualization of fundus, * history of lack of response to ocular beta blocker therapy, * uncontrolled intraocular pressure, * angle closure glaucoma or occludable angles, * retinal detachment, macular hole, progressive vision loss, any progressive retinal disease or neurologic disease other than glaucoma that is likely to worsen visual field or acuity during the course of the study, * a history of, or any current condition contraindicated with use of a beta blocker (e.g., chronic obstructive pulmonary disease, bronchial asthma, congestive heart failure, myasthenia gravis, hypoglycemia, bradycardia, etc), * chronic use of steroids, * any disease that, in the opinion of the investigator, may put the patient at significant risk, * taking systemic beta blockers

Keywords: glaucoma, open angle, ocular hypertension, beta blocker, beta adrenergic, intraocular pressure
expanded access [ga-68] psma-11 pet imaging

Conditions: Prostate Cancer

Summary: in this expanded access ind study, mayo clinic in rochester mn offers \[ga-68\] psma-11 pet/ct or pet/mr imaging to patients who meet criteria.

\[ga-68\] psma-11 pet/ct and pet/mr imaging has been shown to allow for accurate detection of metastatic prostate cancer at the time of initial diagnosis and staging of patients with high-risk prostate cancer and at the time of biochemical recurrence. in addition, available data show superiority of metastatic lesion detection with \[ga-68\] psma-11 pet over conventional imaging. this improved lesion detection has a direct impact on selection of anti-cancer therapy and thus may improve patient outcomes. under expanded access ind, enrolled patients will receive a clinical \[68ga\] psma-11 pet/ct or pet/mr for evaluation of their cancer. imaging exams must be deemed clinically indicated by a referring provider. patients will be responsible for the cost of the imaging exam. access is limited.

Eligibility criteria:
participant groups there are two participant groups; please refer to the inclusion details below: group 1: untreated high-risk prostate cancer group (must meet at least one of the following inclusion criteria): 1. serum prostate-specific antigen (psa) concentration of 20 ng/ml or more 2. pathologic criteria of international society of uropathology (isup) grade group 3-5 (isup grades 3-5 are equivalent to pathologic gleason scores of 4+3, 8, 9 or 10) 3. local staging of t3 or worse (indicating that cancer has invaded into tissues outside of the prostate gland, as seen at either ct or mri) biochemically recurrent prostate cancer group (must meet one of the criteria): 1. in patients who have undergone a prostatectomy, psa \> 0.2 ng/ml on 2 consecutive tests 2. in patients who have undergone definitive prostate radiation, psa rise ≥ 2 ng/ml above the nadir psa exclusion criteria: current exclusion criteria for both groups includes: 1. patients unable to sign informed consent 2. patient with a life expectancy less than 6 months 3. additional exclusion criteria may be added based on demand